$HBIO
HARVARD BIOSCIENCE INC

2012 Q4 Form 10-Q Financial Statement

#000119312512460243 Filed on November 08, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $28.25M $26.10M $26.38M
YoY Change -2.68% -1.05% -0.27%
Cost Of Revenue $14.86M $14.14M $14.50M
YoY Change -5.97% -2.54% 4.44%
Gross Profit $13.39M $11.97M $11.88M
YoY Change 1.25% 0.77% -5.48%
Gross Profit Margin 47.41% 45.85% 45.02%
Selling, General & Admin $8.330M $9.502M $8.921M
YoY Change -13.32% 6.51% 4.85%
% of Gross Profit 62.2% 79.39% 75.11%
Research & Development -$1.210M $1.861M $1.554M
YoY Change -181.21% 19.76% 25.32%
% of Gross Profit -9.03% 15.55% 13.08%
Depreciation & Amortization $1.070M $1.020M $1.110M
YoY Change -4.46% -8.11% 11.0%
% of Gross Profit 7.99% 8.52% 9.35%
Operating Expenses $11.26M $10.81M $11.66M
YoY Change -4.94% -7.25% 9.73%
Operating Profit $2.138M $1.156M $220.0K
YoY Change 54.03% 425.45% -88.68%
Interest Expense -$160.0K $147.0K $216.0K
YoY Change 23.08% -31.94% 10.2%
% of Operating Profit -7.48% 12.72% 98.18%
Other Income/Expense, Net -$149.0K -$178.0K -$338.0K
YoY Change -63.03% -47.34% -11.05%
Pretax Income $1.989M $978.0K -$118.0K
YoY Change 101.93% -928.81% -107.55%
Income Tax $817.0K $278.0K -$146.0K
% Of Pretax Income 41.08% 28.43%
Net Earnings $1.200M -$133.0K $28.00K
YoY Change 62.6% -575.0% -99.78%
Net Earnings / Revenue 4.25% -0.51% 0.11%
Basic Earnings Per Share $0.04 -$0.01 $0.00
Diluted Earnings Per Share $0.04 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 28.82M shares 28.80M shares 28.49M shares
Diluted Shares Outstanding 28.80M shares 29.90M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.70M $20.30M $16.20M
YoY Change 15.64% 25.31% -5.81%
Cash & Equivalents $20.68M $20.29M $16.24M
Short-Term Investments
Other Short-Term Assets $4.619M $2.996M $2.718M
YoY Change 84.69% 10.23% -9.4%
Inventory $17.76M $17.99M $20.10M
Prepaid Expenses
Receivables $14.36M $13.60M $13.62M
Other Receivables $4.600M $3.000M $2.700M
Total Short-Term Assets $58.97M $58.76M $58.43M
YoY Change 2.45% 0.58% 9.82%
LONG-TERM ASSETS
Property, Plant & Equipment $4.551M $4.097M $3.082M
YoY Change 47.47% 32.93% -6.61%
Goodwill $36.20M $35.95M $35.74M
YoY Change 5.82% 0.57%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $490.0K $67.00K $246.0K
YoY Change 127.91% -72.76% -96.72%
Total Long-Term Assets $74.51M $71.82M $68.54M
YoY Change 7.88% 4.78% 2.15%
TOTAL ASSETS
Total Short-Term Assets $58.97M $58.76M $58.43M
Total Long-Term Assets $74.51M $71.82M $68.54M
Total Assets $133.5M $130.6M $127.0M
YoY Change 5.41% 2.84% 5.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.680M $4.141M $5.265M
YoY Change -5.63% -21.35% 12.02%
Accrued Expenses $3.505M $3.766M $3.800M
YoY Change 5.48% -0.89% -2.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $9.901M $9.531M $10.22M
YoY Change 3.58% -6.7% 4.23%
LONG-TERM LIABILITIES
Long-Term Debt $12.95M $15.30M $16.31M
YoY Change -20.55% -6.16% -9.42%
Other Long-Term Liabilities $6.100M $4.900M $3.500M
YoY Change 24.49% 40.0% -12.5%
Total Long-Term Liabilities $12.95M $15.30M $16.31M
YoY Change -20.55% -6.16% -25.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.901M $9.531M $10.22M
Total Long-Term Liabilities $12.95M $15.30M $16.31M
Total Liabilities $29.27M $30.22M $30.99M
YoY Change -5.99% -2.49% -2.85%
SHAREHOLDERS EQUITY
Retained Earnings -$77.26M -$78.46M -$80.37M
YoY Change -2.98% -2.37%
Common Stock $197.0M $194.2M $190.6M
YoY Change 2.86% 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 7.746M shares 7.746M shares 7.746M shares
Shareholders Equity $104.2M $100.4M $95.98M
YoY Change
Total Liabilities & Shareholders Equity $133.5M $130.6M $127.0M
YoY Change 5.41% 2.84% 5.54%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income $1.200M -$133.0K $28.00K
YoY Change 62.6% -575.0% -99.78%
Depreciation, Depletion And Amortization $1.070M $1.020M $1.110M
YoY Change -4.46% -8.11% 11.0%
Cash From Operating Activities $1.400M $2.510M $1.210M
YoY Change -46.97% 107.44% -34.59%
INVESTING ACTIVITIES
Capital Expenditures -$680.0K -$540.0K -$300.0K
YoY Change 51.11% 80.0% 57.89%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $30.00K -$5.160M
YoY Change -93.33% -100.58% 11.45%
Cash From Investing Activities -$700.0K -$510.0K -$5.460M
YoY Change -6.67% -90.66% 13.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -520.0K -740.0K -680.0K
YoY Change -572.73% 8.82% -118.84%
NET CHANGE
Cash From Operating Activities 1.400M 2.510M 1.210M
Cash From Investing Activities -700.0K -510.0K -5.460M
Cash From Financing Activities -520.0K -740.0K -680.0K
Net Change In Cash 180.0K 1.260M -4.930M
YoY Change -91.0% -125.56% -870.31%
FREE CASH FLOW
Cash From Operating Activities $1.400M $2.510M $1.210M
Capital Expenditures -$680.0K -$540.0K -$300.0K
Free Cash Flow $2.080M $3.050M $1.510M
YoY Change -32.69% 101.99% -25.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-12
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20285000 USD
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13602000 USD
CY2012Q3 us-gaap Inventory Net
InventoryNet
17992000 USD
CY2012Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3887000 USD
CY2012Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2996000 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28822767 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001123494
dei Entity Registrant Name
EntityRegistrantName
HARVARD BIOSCIENCE INC
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
CY2012Q3 us-gaap Assets Current
AssetsCurrent
58762000 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4097000 USD
CY2012Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
8635000 USD
CY2012Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21805000 USD
CY2012Q3 us-gaap Goodwill
Goodwill
35946000 USD
CY2012Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1268000 USD
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
67000 USD
CY2012Q3 us-gaap Assets
Assets
130580000 USD
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4141000 USD
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
585000 USD
CY2012Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
438000 USD
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3766000 USD
CY2012Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
601000 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9531000 USD
CY2012Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15300000 USD
CY2012Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
537000 USD
CY2012Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
4850000 USD
CY2012Q3 us-gaap Liabilities
Liabilities
30218000 USD
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193862000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78462000 USD
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4734000 USD
CY2012Q3 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130580000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17916000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15078000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
18160000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3908000 USD
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2501000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
57563000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3086000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7925000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22367000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
34209000 USD
CY2011Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1269000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000 USD
CY2011Q4 us-gaap Assets
Assets
126634000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4959000 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
483000 USD
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
251000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3323000 USD
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
543000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9559000 USD
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16300000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
369000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
4907000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
31135000 USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191157000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79630000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5722000 USD
CY2011Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126634000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
302000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36289170 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28543663 shares
CY2011Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2012Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
202000 USD
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36564274 shares
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28818767 shares
CY2012Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
364000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
362000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
100362000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
95499000 USD
CY2011Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
16300000 USD
CY2012Q3 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
15300000 USD
CY2012Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
4700000 USD
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
us-gaap Revenues
Revenues
82922000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
43913000 USD
us-gaap Gross Profit
GrossProfit
39009000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14182000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14593000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5549000 USD
us-gaap Restructuring Charges
RestructuringCharges
166000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2071000 USD
us-gaap Operating Expenses
OperatingExpenses
36561000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
2448000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-86000 USD
us-gaap Interest Expense
InterestExpense
447000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
37000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-294000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-790000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1658000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
490000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2012Q3 us-gaap Revenues
Revenues
26104000 USD
CY2012Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14110000 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
11994000 USD
CY2012Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4670000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4832000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1861000 USD
CY2012Q3 us-gaap Restructuring Charges
RestructuringCharges
29000 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
681000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
12073000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-79000 USD
CY2012Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-29000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
147000 USD
CY2012Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
11000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-178000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-257000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-124000 USD
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2011Q3 us-gaap Revenues
Revenues
26381000 USD
CY2011Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14503000 USD
CY2011Q3 us-gaap Gross Profit
GrossProfit
11878000 USD
CY2011Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4361000 USD
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4560000 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1554000 USD
CY2011Q3 us-gaap Restructuring Charges
RestructuringCharges
477000 USD
CY2011Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
706000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
11658000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
220000 USD
CY2011Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000 USD
CY2011Q3 us-gaap Interest Expense
InterestExpense
216000 USD
CY2011Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
17000 USD
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000 USD
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-338000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-118000 USD
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-146000 USD
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42804000 USD
us-gaap Revenues
Revenues
79837000 USD
us-gaap Gross Profit
GrossProfit
37033000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12809000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13122000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3948000 USD
us-gaap Restructuring Charges
RestructuringCharges
449000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2016000 USD
us-gaap Operating Expenses
OperatingExpenses
32344000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
4689000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-44000 USD
us-gaap Interest Expense
InterestExpense
602000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
48000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-534000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1132000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3557000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
483000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-133000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
28000 USD
us-gaap Net Income Loss
NetIncomeLoss
1168000 USD
us-gaap Net Income Loss
NetIncomeLoss
3074000 USD
CY2012Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1444000 USD
CY2011Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1837000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
988000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
335000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1311000 USD
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1809000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2156000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3409000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2373000 USD
us-gaap Depreciation
Depreciation
930000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
28000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
139000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-23000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-628000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1841000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-861000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
107000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1196000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-21000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-342000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
58000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-494000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6656000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-1151000 USD
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
36000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2863000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3978000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
500000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
461000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
230000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2369000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-539000 USD
us-gaap Interest Paid
InterestPaid
411000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-93000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-877000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4005000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-1152000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2064000 USD
us-gaap Depreciation
Depreciation
969000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
35000 USD
hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
226000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-294000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1910000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3460000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
445000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
321000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-291000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1427000 USD
hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-154000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
21000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
5165000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6450000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1703000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
449000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1254000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
232000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3467000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16237000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19704000 USD
us-gaap Interest Paid
InterestPaid
491000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1142000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1574000 USD
hbio Non Cash Restructuring Credit Charge
NonCashRestructuringCreditCharge
-13000 USD
hbio Non Cash Restructuring Credit Charge
NonCashRestructuringCreditCharge
280000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<p style='margin-top:13.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:-0.0500000000000007px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements </font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:24.5px;">In </font><font style="font-family:Times New Roman;font-size:10pt;">July 2012</font><font style="font-family:Times New Roman;font-size:10pt;">, the FASB issued Accounting Standards Update No.&#160;201</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">-0</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Intangibles- Goodwill and Other</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">- Testing Indefinite-Lived Intangible Assets for Impairment</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> (ASU 201</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">0</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Under the amendments in this </font><font style="font-family:Times New Roman;font-size:10pt;">u</font><font style="font-family:Times New Roman;font-size:10pt;">pdate, </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">Company</font><font style="font-family:Times New Roman;font-size:10pt;"> has the option </font><font style="font-family:Times New Roman;font-size:10pt;">first </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">assess qualitative factors to determine </font><font style="font-family:Times New Roman;font-size:10pt;">whether the existence of events or circumstances</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">leads to a</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">determination that it is more likely than not that the </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset is impaired</font><font style="font-family:Times New Roman;font-size:10pt;">. If, after assessing the totality of</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">events or circumstances, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">concludes that</font><font style="font-family:Times New Roman;font-size:10pt;"> it is not more likely than not that</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset is impaired, </font><font style="font-family:Times New Roman;font-size:10pt;">then </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">Company</font><font style="font-family:Times New Roman;font-size:10pt;"> is not required to take further action</font><font style="font-family:Times New Roman;font-size:10pt;">. However, if </font><font style="font-family:Times New Roman;font-size:10pt;">the Company </font><font style="font-family:Times New Roman;font-size:10pt;">concludes</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">otherwise, then it is required to </font><font style="font-family:Times New Roman;font-size:10pt;">determine the </font><font style="font-family:Times New Roman;font-size:10pt;">fair value of the</font><font style="font-family:Times New Roman;font-size:10pt;"> indefinite-lived intangible asset</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and perform the quantitative impairment test by</font><font style="font-family:Times New Roman;font-size:10pt;"> comparing the fair value</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">with the carrying amount</font><font style="font-family:Times New Roman;font-size:10pt;"> in accordance with subtopic </font><font style="font-family:Times New Roman;font-size:10pt;">350-</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">0. Under the amendments in this </font><font style="font-family:Times New Roman;font-size:10pt;">u</font><font style="font-family:Times New Roman;font-size:10pt;">pdate, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company</font><font style="font-family:Times New Roman;font-size:10pt;"> has the option to</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">bypass the qualitative assessment for any </font><font style="font-family:Times New Roman;font-size:10pt;">indefinite-lived intangible asset</font><font style="font-family:Times New Roman;font-size:10pt;"> in any period and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">proceed directly to performing the </font><font style="font-family:Times New Roman;font-size:10pt;">quantitative impairment test</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The Company </font><font style="font-family:Times New Roman;font-size:10pt;">may resume performing the qualitative assessment in any</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">subsequent period</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The provisions of this update will be effective for </font><font style="font-family:Times New Roman;font-size:10pt;">the Company </font><font style="font-family:Times New Roman;font-size:10pt;">in fiscal years beginning after </font><font style="font-family:Times New Roman;font-size:10pt;">September</font><font style="font-family:Times New Roman;font-size:10pt;">&#160;15, 201</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">, and for the interim periods within fiscal years with early adoption permitted. </font><font style="font-family:Times New Roman;font-size:10pt;">The Company</font><font style="font-family:Times New Roman;font-size:10pt;"> believe</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">adoption of this new guidance will not have a material impact on </font><font style="font-family:Times New Roman;font-size:10pt;">its</font><font style="font-family:Times New Roman;font-size:10pt;"> consolidated results of operations or financial position.</font></p>
CY2012Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
40938000 USD
CY2012Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19133000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16884000 USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
39251000 USD
CY2012Q3 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
37214000 USD
CY2011Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
35478000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
1346000 USD
us-gaap Future Amortization Expense Year One
FutureAmortizationExpenseYearOne
2800000 USD
us-gaap Future Amortization Expense Year Two
FutureAmortizationExpenseYearTwo
2600000 USD
us-gaap Future Amortization Expense Year Three
FutureAmortizationExpenseYearThree
2500000 USD
us-gaap Future Amortization Expense Year Four
FutureAmortizationExpenseYearFour
2200000 USD
us-gaap Future Amortization Expense Year Five
FutureAmortizationExpenseYearFive
2100000 USD
us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
391000 USD
CY2012Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7980000 USD
CY2012Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
932000 USD
CY2012Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
9080000 USD
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8372000 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
626000 USD
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9162000 USD
CY2012Q3 hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
100000 USD
hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
300000 USD
CY2010Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
158000 USD
CY2011 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-46000 USD
CY2011 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
32000 USD
CY2011Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
144000 USD
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-114000 USD
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
170000 USD
CY2012Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
200000 USD
CY2012Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
83000 USD
CY2012Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
214000 USD
CY2012Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
147000 USD
CY2012Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-56000 USD
CY2012Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
206000 USD
CY2011Q3 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
59000 USD
CY2011Q3 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
200000 USD
CY2011Q3 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
148000 USD
CY2011Q3 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-34000 USD
CY2011Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
145000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
241000 USD
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
600000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
414000 USD
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-156000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
583000 USD
us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
171000 USD
us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
624000 USD
us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
463000 USD
us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-106000 USD
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
438000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
700000 USD
CY2012Q3 us-gaap Defined Benefit Plan Estimated Future Employer Contributions In Current Fiscal Year
DefinedBenefitPlanEstimatedFutureEmployerContributionsInCurrentFiscalYear
200000 USD
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
600000 USD
CY2012Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2011Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2012Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
4900000 USD
CY2011Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
4900000 USD
hbio Estimated Rental Expenses Current Year
EstimatedRentalExpensesCurrentYear
1200000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1064000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1021000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
901000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
679000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
418000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
130000 USD
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4213000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000 USD
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2700645 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8519575 shares
CY2011Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1210934 shares
hbio Stock Options And Restricted Stock Units Issued
StockOptionsAndRestrictedStockUnitsIssued
1560229 shares
hbio Fungible Share Adjustment For Restricted Stock Units Granted
FungibleShareAdjustmentForRestrictedStockUnitsGranted
-275943 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-123000 shares
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
45912 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
-6.45
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8644009 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1932456 shares
CY2012Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.19
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.09
hbio Stock Options And Restricted Stock Units Cancelled
StockOptionsAndRestrictedStockUnitsCancelled
1010962 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-47462 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
4.21
hbio Fungible Share Adjustment For Restricted Stock Units Cancelled
FungibleShareAdjustmentForRestrictedStockUnitsCancelled
11109 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-963500 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
677193 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
539450 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
349295 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-164090 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.57
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.32
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.97
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5509
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5424
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0201
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm
5.94
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
958000 USD
CY2011Q3 us-gaap Share Based Compensation
ShareBasedCompensation
853000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2373000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2064000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28435483 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1426015 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29861498 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8644009 shares
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4006054 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4643163 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3469499 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28797887 shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28797887 shares
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28488692 shares
CY2011Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1407337 shares
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29896029 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28758621 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
928743 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29687364 shares
CY2012Q3 hbio Employee Stock Purchase Plan Shares Authorized
EmployeeStockPurchasePlanSharesAuthorized
500000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
25597 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
22587 shares
CY2012Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2011Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
435972 shares
us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term
DeferredCompensationArrangementWithIndividualMaximumContractualTerm
10 years
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodMaximum
4 years
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2012Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2011Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2012Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000 USD
CY2012Q3 hbio Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold
LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold
6000000 USD
CY2012Q3 hbio Lender Approval To Fund Acquisition With Equity In Excess Of Threshold
LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold
10000000 USD
hbio Interest Rate In Excess Of Libor On Credit Facility
InterestRateInExcessOfLiborOnCreditFacility
0.0300
CY2012Q3 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0322
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2960
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
700000 USD
CY2011 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
500000 USD
CY2011Q3 us-gaap Assets
Assets
126968000 USD
CY2012Q3 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
CY2011Q3 us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD
us-gaap Revenues From Transactions With Other Operating Segments Of Same Entity
RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity
0 USD

Files In Submission

Name View Source Status
0001193125-12-460243-index-headers.html Edgar Link pending
0001193125-12-460243-index.html Edgar Link pending
0001193125-12-460243.txt Edgar Link pending
0001193125-12-460243-xbrl.zip Edgar Link pending
d409397d10q.htm Edgar Link pending
d409397dex311.htm Edgar Link pending
d409397dex312.htm Edgar Link pending
d409397dex321.htm Edgar Link pending
d409397dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
hbio-20120930.xml Edgar Link completed
hbio-20120930.xsd Edgar Link pending
hbio-20120930_cal.xml Edgar Link unprocessable
hbio-20120930_def.xml Edgar Link unprocessable
hbio-20120930_lab.xml Edgar Link unprocessable
hbio-20120930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending